Menu
Enrolling by invitation NCT06906536

Examining the Effect of Acute Intermittent Hypoxia on Serum Blood Proteins and Lower Limb Function

No phase Interventional INCOMPLETE SPINAL CORD INJURY (ASIA D) Able Bodied

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Acute Intermittent Hypoxia (AIH).
Who it may be relevant to
Registry conditions: INCOMPLETE SPINAL CORD INJURY (ASIA D), Able Bodied. Basic parameters: 18 years — 75 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Official title

Examining the Effect of Acute Intermittent Hypoxia on Serum Blood Proteins, Corticospinal Excitability, and Force Control in Persons With Incomplete Spinal Cord Injury

Overview

The goal of this study is to clarify mechanisms of acute intermittent hypoxia and to examine the effect on lower limb function in persons with chronic, incomplete spinal cord injury.

Detailed description

The goal of this study is to clarify mechanisms of acute intermittent hypoxia by examining changes in blood biomarkers, neural excitability, and hemoglobin mass. We also aim to clarify how these changes relate to changes in lower limb function in persons with chronic, incomplete spinal cord injury by measuring force steadiness and voluntary muscle activation.

Interventions

  • Other Acute Intermittent Hypoxia (AIH)
    4 consecutive days of 15, 1.5 min episodes at 9% O2 (AIH) alternating with 21% O2 at 1 min intervals

Primary outcome measures

  • Change in Serum Blood Brain Derived Neurotrophic Factor [Time frame: Baseline, Day 1, Day 3, and Day 4]
  • Change in Serum Serotonin [Time frame: Baseline, Day 1, Day 3, and Day 4]
  • Change in the Transcranial Magnetic Stimulation Recruitment Curve Slope [Time frame: Baseline and Day 4]
  • Change in Force Steadiness [Time frame: Baseline and Day 4]
  • Change in Central Activation Ratio [Time frame: Baseline and Day 4]
  • Change in hemoglobin mass [Time frame: Baseline and Day 4]
  • Change in Serum Erythropoetin [Time frame: Baseline, Day 1, Day 3, and Day 4]
Secondary outcome measures (3)
  • Axial damage ratio [Time frame: Baseline]
  • 6-Minute Walk Test [Time frame: Baseline and Day 4]
  • 10-Meter Walk Test [Time frame: Baseline and Day 4]

Eligibility criteria

Inclusion criteria

  • 18 to 75 years old (the latter to reduce likelihood of heart disease)
  • Medically stable with medical clearance from physician to participate
  • Motor-incomplete spinal cord injuries at or below C2 and at or above L5
  • AIS A-D at initial screen, or other non-traumatic spinal cord injury disorders (e.g. multiple sclerosis, ALS, tumors, acute transverse myelitis, etc.)
  • More than 1 year since iSCI to minimize confounds of spontaneous neurological recovery
  • Ability to advance one step overground with or without assistive devices;

Exclusion criteria

  • Severe concurrent illness or pain
  • Recurrent autonomic dysreflexia
  • History of cardiovascular/pulmonary complications
  • Concurrent physical therapy
  • Pregnant at time of enrollment or planning to become pregnant
  • Untreated painful musculoskeletal dysfunction, fracture or pressure sore
  • History of seizures or epilepsy
  • Recurring headaches
  • Concussion within the last six months
  • Depression or manic disorder
  • Metal implants in the head, or pacemaker
  • Aversion to needles

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: Yes

Study design

Allocation
Non-randomized
Model
Parallel assignment
Masking
Single blind
Primary purpose
Treatment

Study locations

United States · 1 center
  • Andrew Tan — Boulder

Identifiers

NCT: NCT06906536 · 23-1275 · 1R03HD115657-01

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗